Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration-Reference-Cited by-同舟云学术

Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration

Published:2023-11 Issue:11 Volume:10 Page:e723-e732
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Rein Sophia M,Lodi Sara,Logan Roger W,Touloumi Giota,Antoniadou Anastasia,Wittkop Linda,Bonnet Fabrice,van Sighem Ard,van der Valk Marc,Reiss Peter,Klein Marina B,Young James,Jarrin Inmaculada,d'Arminio Monforte Antonella,Tavelli Alessandro,Meyer Laurence,Tran Laurent,Gill Michael J,Lang Raynell,Surial Bernard,Haas Andreas D,Justice Amy C,Rentsch Christopher T,Phillips Andrew,Sabin Caroline A,Miro Jose M,Trickey Adam,Ingle Suzanne M,Sterne Jonathan A C,Hernán Miguel A

Funder

National Institute of Allergy and Infectious Diseases

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference32 articles.

1. Consolidated guidelines on HIV prevention, testing, treatment, service delivery, and monitoring: recommendations for a public health approach,2021

2. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon;Calmy;Lancet HIV,2020

3. Dolutegravir plus two different prodrugs of tenofovir to treat HIV;Venter;N Engl J Med,2019

4. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study

5. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study;Clotet;Lancet,2014

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in Atherosclerotic Cardiovascular Disease Risk Scores in a Predominantly Black Cohort with HIV and Associated Comorbidities: A Preliminary Study;Cardiology;2024-08-06

2. Steatotic liver disease and HIV: an agenda for 2030;The Lancet HIV;2024-08

3. Exercise to Prevent Accelerated Vascular Aging in People Living With HIV;Circulation Research;2024-05-24

4. Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study;HIV Medicine;2024-05-15

5. Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study;Viruses;2024-04-15